| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 04.12.2006 (6506
dage). |
Ingen historik.
| Branche | | Fremstilling af farmaceutiske præparater (212000). |
| Sidst opdateret den 12.03.2015 og
angivet som gældende fra 01.01.2015 (3556
dage). |
| Historik | Start | Stop |
|---|
| Fremstilling af farmaceutiske præparater (212000) | 01.01.2015 | |
| Køb og salg af egen fast ejendom (681000) | 01.01.2008 | 31.12.2014 |
| Køb og salg af fast ejendom for egen regning (701200) | 04.12.2006 | 31.12.2007 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.03.2015 og
angivet som gældende fra 04.12.2006 (6506
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | REPONEX PHARMACEUTICALS A/S. |
| Sidst opdateret den 28.05.2018 og
angivet som gældende fra 14.05.2018 (2327
dage). |
| Historik | Start | Stop |
|---|
| REPONEX PHARMACEUTICALS A/S | 14.05.2018 | |
| REPONEX PHARMACEUTICALS ApS | 12.11.2014 | 13.05.2018 |
| TRIFOILIUM ApS | 17.05.2011 | 11.11.2014 |
| WYSPA ApS | 04.12.2006 | 16.05.2011 |
| Binavne | | Heslet Pharma A/S. |
| Sidst opdateret den 28.05.2018 og
angivet som gældende fra 28.05.2018 (2313
dage). |
| Historik | Start | Stop |
|---|
| Heslet Pharma A/S | 28.05.2018 | |
| TRIFOILIUM A/S | 28.05.2018 | |
| HESLET PHARMA ApS | 04.12.2006 | 27.05.2018 |
| TRIFOILIUM ApS | 04.12.2006 | 27.05.2018 |
| Tegningsregel | | Selskabet tegnes af direktøren og formanden for bestyrelsen i forening eller af den samlede bestyrelse. |
| Sidst opdateret den 05.07.2021 og
angivet som gældende fra 04.07.2021 (1180
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | direktøren + formanden |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af direktøren og formanden for bestyrelsen i forening eller af den samlede bestyrelse | 04.07.2021 | |
| Selskabet tegnes af direktøren og et bestyrelsesmedlem i forening eller af formanden for
bestyrelsen og et andet bestyrelsesmedlem i forening eller af den samlede bestyrelse | 18.03.2015 | 03.07.2021 |
| Selskabet tegnes af en direktør | 12.11.2014 | 17.03.2015 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:BDO Statsautoriseret revisionsaktieselskab
Revisionsvirksomhedens CVR-nr.:20222670
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for OpinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and the additionalrequirements applicable in Denmark. Our responsibilities under those standards and requirements arefurther described in the “Auditor’s Responsibilities for the Audit of the Financial Statements” section ofour report. We are independent of the Company in accordance with the International Ethics StandardsBoard for Accountants’ International Code of Ethics for Professional Accountants (including InternationalIndependence Standards) (IESBA Code), together with the ethical requirements that are relevant to ouraudit of the financial statements in Denmark, and we have fulfilled our other ethical responsibilities inaccordance with these requirements and the IESBA Code. We believe that the audit evidence we haveobtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):OpinionWe have audited the financial statements of Reponex Pharmaceuticals A/S for the financial year 1 January-31 December 2023, which comprise statements of comprehensive income, financial position, changes inequity and cash flows, and notes, including material accounting policy information. The financialstatements are prepared in accordance with the IFRS Accounting Standards as adopted by the EU andadditional disclosure requirements in the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Companyat 31 December 2023, and of the results of the operations and cash flows for the financial year 1 January -31 December 2023 in accordance with the IFRS Accounting Standards as adopted by the EU and additionaldisclosure requirements in the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on Management CommentaryManagement is responsible for Management Commentary. Our opinion on the financial statements døs not cover Management Commentary, and we do notexpress any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read ManagementCommentary and, in doing so, consider whether Management Commentary is materially inconsistentwith the financial statements, or our knowledge obtained during the audit, or otherwise appears to bematerially misstated. Moreover, it is our responsibility to consider whether Management Commentary provides theinformation required under the Danish Financial Statements Act. Based on the work performed, we conclude that Management Commentary is in accordance with thefinancial statements and has been prepared in accordance with the requirements of the Danish FinancialStatements Act. We did not identify any material misstatement of the Management Commentary.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Hjemmeside | | www.reponex.dk. |
| Sidst opdateret den 01.03.2023 og
angivet som gældende fra 01.03.2023 (575
dage). |
Ingen historik.
LoginOpret gratis brugere-conomic integration